Ian Bezek

Ian Bezek

InvestorPlace Contributor

Ian Bezek earned his economics degree from Colorado State University in 2010. He then worked as an analyst for Kerrisdale Capital, a New York City-based activist hedge fund, from 2011-13. Since then, Ian has focused on finding under-the-radar investment opportunities, particularly overseas. To that end, he taught himself Spanish and has lived in Mexico and Argentina among other countries. He currently resides in Colombia with his family.

You can interact with Ian on Twitter.

Recent Articles

Robinhood Limits Trading for SNDL Stock: What You Need to Know

By Ian Bezek, InvestorPlace Contributor

Robinhood stopped traders from buying SNDL stock on Thursday. Here's what happened and how things look for Sundial going forward.

7 Safe Stocks to Buy for Solid Returns in Tumultuous Times

By Ian Bezek, InvestorPlace Contributor

While stocks keep going up and up, more risks are mounting under the surface. As such, you should be looking at safe stocks to buy now.

With Earnings Like This, FuelCell Stock Is a Disaster Waiting to Happen

By Ian Bezek, InvestorPlace Contributor

FuelCell delivered another set of underwhelming earnings this month. As such, FCEL stock could sink if the green energy sector cools off.

What You Need to Know About Jaguar Health Stock

By Ian Bezek, InvestorPlace Contributor

Jaguar Health is showing better vital signs lately. However, there are still some things to consider before pouncing on JAGX stock.

The Top 7 Stocks to Buy for Biden’s First 100 Days 

By Ian Bezek, InvestorPlace Contributor

The Biden Administration will look to make a big splash in its first 100 days. These seven Biden stocks to buy should fare well with the new government.

Why Ethereum Is the Most Compelling Alternative to Bitcoin Today

By Ian Bezek, InvestorPlace Contributor

With Ethereum's network getting exponentially faster, it should pave the way for adoption of Ethereum's smart contracts in large numbers.

Novavax’s Insiders Are Selling Stock, And That’s Not a Bad Idea

By Ian Bezek, InvestorPlace Contributor

Novavax has achieved considerable clinical success with its Covid-19 vaccine. However, NVAX stock is too expensive.

Nikola Stock Has Too Much Further to Go to Be Worth Your Money Now

By Ian Bezek, InvestorPlace Contributor

After last year's scandals, Nikola is still soldiering on. However, JP Morgan's optimism for NKLA stock is currently misplaced.

OpenDoor Is Riding Several Huge, Positive Catalysts

By Ian Bezek, InvestorPlace Contributor

There are some valid questions about Opendoor's long-term outlook. But don't overthink it; OpenDoor stock is still heading upward.

Breaking Down Stellar Coin’s Pros and Cons

By Ian Bezek, InvestorPlace Contributor

Stellar coin has soared in recent weeks. However it is still dramatically underperforming against bitcoin. Here's why.

Load More